IP Library › Granted Patent US 12,201,644
Granted Patent B2
US 12,201,644 · App. 17/474,765 · Granted Jan 21, 2025

Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

Inventors: Craig L. Duvall (Nashville, TN); Samantha M. Sarett (Nashville, TN); Thomas A. Werfel (Nashville, TN)
Assignee: Vanderbilt University
A61K31/7105A61K9/0019A61K47/543C07K14/76C12N15/111C12N2310/14C12N2310/141C12N2310/3515C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,644
App. No.
17/474,765
Granted
Jan 21, 2025
Kind
B2
Abstract

Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Claims (3)

1. A compound comprising siRNA functionalized with a dibenzocyclooctyne moiety and directly conjugated to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000].

2. The compound of claim 1 , wherein the compound is complexed with albumin.

3. The compound of claim 1 , wherein the siRNA comprises a guide sequence that is complementary to an antisense sequence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: DUVALL, CRAIG L; SARETT, SAMANTHA M; WERFEL, THOMAS A.
To: VANDERBILT UNIVERSITY
Reel/Frame 057495/0276 →
Continuity (3)
Continuation 15671131 · Aug 7, 2017
Provisional Application 62371619 · Aug 5, 2016
Related Publication 20220241317A1 · Aug 4, 2022
References Cited (14)
US 11104899B2 · Prakash · 2021 [cited by examiner]
US 20080311040A1 · Berry · 2008 [cited by examiner]
US 20150231302A1 · Duvall et al. · 2015 [cited by applicant]
US 20150283254A1 · Duvall et al. · 2015 [cited by applicant]
US 20160058876A1 · Duvall et al. · 2016 [cited by applicant]
US 20160175265A1 · Duvall et al. · 2016 [cited by applicant]
Siu, King S., et al. (“Single-walled carbon nanotubes noncovalently functionalized with lipid modified polyethylenimine for siRNA delivery in vitro and in vivo.” Bioconjugate chemistry 25.10 (2014): 1744-1751). [cited by examiner]
Kim, Hyun-Ki, et al.(Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. International journal of pharmaceutics 392.1-2 (2010): 141-147). [cited by examiner]
Van Delft, Pieter, et al. (“Synthesis of oligoribonucleic acid conjugates using a cyclooctyne phosphoramidite.” Organic letters 12.23 (2010): 5486-5489. [cited by examiner]
Hiki et al. (“A facile synthesis of azido-terminated heterobifunctional poly (ethylene glycol) or “click” conjugation.” Bioconjugate chemistry 18.6 (2007): 2191-2196). [cited by examiner]
Kanasty et al. (“Sequence-defined oligomers from hydroxyproline building blocks for parallel synthesis applications.” Angewandte Chemie International Edition 55.33 (2016): 9529-9533). [cited by examiner]
Bienk K, et al., An albumin-mediated cholesterol design-based strategy for tuning sirna pharmacokinetics and gene silencing. J Control Release (2016) 232:143-151. [cited by applicant]
Kamphorst JJ, et al., Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res (2015) 75:544-553. [cited by applicant]
Lau S, et al., Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation., Mol Pharm (2012) 9:71-80. [cited by applicant]